CN114829939B - 无细胞核小体作为生物标志物的用途 - Google Patents

无细胞核小体作为生物标志物的用途

Info

Publication number
CN114829939B
CN114829939B CN202080083887.9A CN202080083887A CN114829939B CN 114829939 B CN114829939 B CN 114829939B CN 202080083887 A CN202080083887 A CN 202080083887A CN 114829939 B CN114829939 B CN 114829939B
Authority
CN
China
Prior art keywords
cancer
subject
vascular
nucleosomes
nucleosome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080083887.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN114829939A (zh
Inventor
J·V·米卡莱夫
H·威尔逊-罗布尔斯
M·E·埃克莱斯顿
M·C·A·赫尔措
J·B·特雷尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Belgian Volition SPRL
Original Assignee
Belgian Volition SPRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Belgian Volition SPRL filed Critical Belgian Volition SPRL
Publication of CN114829939A publication Critical patent/CN114829939A/zh
Application granted granted Critical
Publication of CN114829939B publication Critical patent/CN114829939B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875Nucleoproteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080083887.9A 2019-12-02 2020-12-02 无细胞核小体作为生物标志物的用途 Active CN114829939B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962942596P 2019-12-02 2019-12-02
US62/942596 2019-12-02
US202063088408P 2020-10-06 2020-10-06
US63/088408 2020-10-06
PCT/EP2020/084328 WO2021110776A1 (en) 2019-12-02 2020-12-02 Use of cell free nucleosomes as biomarkers

Publications (2)

Publication Number Publication Date
CN114829939A CN114829939A (zh) 2022-07-29
CN114829939B true CN114829939B (zh) 2025-10-21

Family

ID=73698838

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080083887.9A Active CN114829939B (zh) 2019-12-02 2020-12-02 无细胞核小体作为生物标志物的用途

Country Status (15)

Country Link
US (1) US20230003735A1 (https=)
EP (2) EP4435431A3 (https=)
JP (2) JP7693670B2 (https=)
KR (1) KR102930652B1 (https=)
CN (1) CN114829939B (https=)
AU (1) AU2020395504A1 (https=)
BR (1) BR112022010774A2 (https=)
CA (1) CA3163181A1 (https=)
ES (1) ES2988371T3 (https=)
IL (1) IL293342B1 (https=)
MX (1) MX2022006655A (https=)
PL (1) PL4070111T3 (https=)
TW (1) TWI902730B (https=)
WO (1) WO2021110776A1 (https=)
ZA (1) ZA202205916B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2820129A1 (en) * 2012-03-02 2015-01-07 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
EP3736344A1 (en) 2014-03-13 2020-11-11 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
JP2024542996A (ja) 2021-10-29 2024-11-19 ベルジアン ボリション エスアールエル 均一系免疫アッセイ法
GB202117799D0 (en) 2021-12-09 2022-01-26 Belgian Volition Srl Method for the detection of blood cancer
EP4490323A1 (en) 2022-03-11 2025-01-15 Belgian Volition SRL Differential diagnosis method
WO2024042210A1 (en) 2022-08-25 2024-02-29 Belgian Volition Srl Method for measuring cell free chromatin
EP4639173A1 (en) * 2022-12-19 2025-10-29 Belgian Volition SRL Calibration

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108496083A (zh) * 2015-10-21 2018-09-04 比利时意志有限责任公司 用于检测包含组蛋白修饰和变体的核小体的方法
CN108603884A (zh) * 2015-10-21 2018-09-28 比利时意志有限责任公司 富集无细胞核小体的方法
WO2019169263A1 (en) * 2018-03-01 2019-09-06 Epicypher, Inc. Quantification of nucleosome modifications using chemically-defined recombinant nucleosomes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0319376D0 (en) 2003-08-18 2003-09-17 Chroma Therapeutics Ltd Histone modification detection
GB0413732D0 (en) * 2004-06-13 2004-07-21 Chroma Therapeutics Ltd Histone modification
ATE534908T1 (de) * 2009-08-03 2011-12-15 Universitaetsklinikum Freiburg Verfahren und verbindungen zur diagnose und behandlung von krebs
GB201115098D0 (en) 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
GB201115095D0 (en) 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
GB201115099D0 (en) 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes
PT2788767T (pt) 2011-12-07 2017-12-06 Belgian Volition Sprl Método de detecção de adutos de nucleosoma
EP2820129A1 (en) * 2012-03-02 2015-01-07 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9388213B2 (en) * 2012-09-10 2016-07-12 The Rockefeller University Polycomb repressive complex 2 (PRC2) inhibitors and uses thereof
CN107209190B (zh) * 2014-10-29 2021-07-16 比利时意志有限责任公司 用于富集循环肿瘤dna的方法
GB201511512D0 (en) * 2015-07-01 2015-08-12 Singapore Volition Pte Ltd Use of cell-free nucleosomes as biomarkers
GB201511542D0 (en) * 2015-07-01 2015-08-12 Singapore Volition Pte Ltd Use of cell free nucleosomes as biomarkers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108496083A (zh) * 2015-10-21 2018-09-04 比利时意志有限责任公司 用于检测包含组蛋白修饰和变体的核小体的方法
CN108603884A (zh) * 2015-10-21 2018-09-28 比利时意志有限责任公司 富集无细胞核小体的方法
WO2019169263A1 (en) * 2018-03-01 2019-09-06 Epicypher, Inc. Quantification of nucleosome modifications using chemically-defined recombinant nucleosomes

Also Published As

Publication number Publication date
EP4070111A1 (en) 2022-10-12
MX2022006655A (es) 2022-09-07
KR102930652B1 (ko) 2026-02-25
TW202134654A (zh) 2021-09-16
IL293342B1 (en) 2026-01-01
AU2020395504A1 (en) 2022-06-23
ES2988371T3 (es) 2024-11-20
JP7693670B2 (ja) 2025-06-17
CA3163181A1 (en) 2021-06-10
US20230003735A1 (en) 2023-01-05
EP4070111B1 (en) 2024-08-21
BR112022010774A2 (pt) 2022-08-23
KR20220110794A (ko) 2022-08-09
JP2025124845A (ja) 2025-08-26
JP2023503379A (ja) 2023-01-27
PL4070111T3 (pl) 2025-02-03
EP4435431A3 (en) 2024-10-16
EP4435431A2 (en) 2024-09-25
CN114829939A (zh) 2022-07-29
IL293342A (en) 2022-07-01
WO2021110776A1 (en) 2021-06-10
TWI902730B (zh) 2025-11-01
ZA202205916B (en) 2024-09-25
EP4070111C0 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
CN114829939B (zh) 无细胞核小体作为生物标志物的用途
KR102442803B1 (ko) 결장직장암에 대한 복합 테스트
US20240019432A1 (en) Diagnostic method for multiple sclerosis
EP3963330B1 (en) Method for the detection of prostate cancer
WO2022152786A1 (en) Method for the detection of lung cancer
US20250197944A1 (en) Differential diagnosis method
EP3963331B1 (en) Method for the detection of cancer
HK40085725A (en) Use of cell free nucleosomes as biomarkers
HK40085725B (en) Use of cell free nucleosomes as biomarkers
EA047224B1 (ru) Применение бесклеточных нуклеосом в качестве биомаркеров
US20250231194A1 (en) Method for transplant organ health assessment
WO2024240939A1 (en) Use of cell free nucleosomes as biomarkers
WO2024223947A1 (en) Use of cell free nucleosomes as biomarkers of carcinomas
EA049714B1 (ru) Способ триажа с использованием бесклеточных нуклеосомных уровней

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant